[en] Currently, there are no disease-modifying therapies available for Alzheimer's disease (AD). Acetylcholinesterase inhibitors and memantine are licensed for AD and have moderate symptomatic benefits. Epidemiological studies have suggested that NSAIDs, estrogen, HMG-CoA reductase inhibitors (statins) or tocopherol (vitamin E) can prevent AD. However, prospective, randomised studies have not convincingly been able to demonstrate clinical efficacy. Major progress in molecular medicine suggests further drug targets. The metabolism of the amyloid-precursor protein and the aggregation of its Abeta fragment are the focus of current studies. Abeta peptides are produced by the enzymes beta- and gamma-secretase. Inhibition of gamma-secretase has been shown to reduce Abeta production. However, gamma-secretase activity is also involved in other vital physiological pathways. Involvement of gamma-secretase in cell differentiation may preclude complete blockade of gamma-secretase for prolonged times in vivo. Inhibition of beta-secretase seems to be devoid of serious adverse effects according to studies with knockout animals. However, targeting beta-secretase is hampered by the lack of suitable inhibitors to date. Other approaches focus on enzymes that cut inside the Abeta sequence such as alpha-secretase and neprilysin. Stimulation of the expression or activity of alpha-secretase or neprilysin has been shown to enhance Abeta degradation. Furthermore, inhibitors of Abeta aggregation have been described and clinical trials have been initiated. Peroxisome proliferator activated receptor-gamma agonists and selected NSAIDs may be suitable to modulate both Abeta production and inflammatory activation. On the basis of autopsy reports, active immunisation against Abeta in humans seems to have proven its ability to clear amyloid deposits from the brain. However, a first clinical trial with active vaccination against the full length Abeta peptide has been halted because of adverse effects. Further trials with vaccination or passive transfer of antibodies are planned.
Disciplines :
Neurologie
Auteur, co-auteur :
Hüll, Michael; Department of Psychiatry and Psychotherapy, University of Freiburg, Hauptstrasse 5, D-79108 Freiburg, Germany. michael.huell@uniklinik-freiburg.de
Fillit HM, O'Connell AW, Brown WM, et al. Barriers to drug discovery and development for Alzheimer disease. Alzheimer Dis Assoc Disord 2002; 16 Suppl. 1: S1-8
Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366 (9503): 2112-7
Bond J, Stave C, Sganga A, et al. Inequalities in dementia care across Europe: key findings of the Facing Dementia Survey. Int J Clin Pract Suppl 2005; (146): 8-14
Fillit H, Hill J. Economics of dementia and pharmacoeconomics of dementia therapy. Am J Geriatr Pharmacother 2005; 3 (1): 39-49
Ferris SH. Clinical trials in AD: are current formats and outcome measures adequate? Alzheimer Dis Assoc Disord 2002; 16 Suppl. 1: S13-17
Dickerson BC, Sperling RA. Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease. NeuroRx 2005; 2 (2): 348-60
Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 2004; 1 (2): 213-25
Thal LJ, Kantarci K, Reiman EM, et al. The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord 2006; 20 (1): 6-15
McDermott MP, Hall WJ, Oakes D, et al. Design and analysis of two-period studies of potentially disease-modifying treatments. Control Clin Trials 2002; 23 (6): 635-49
Jack CR, Slomkowski M, Gracon S, et al. MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology 2003; 60 (2): 253-60
Areosa SA, Sherriff F, McShane R. Memantine for dementia. Cochrane Database Syst Rev 2005; (2): CD003154
Birks J, Harvey R. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 2006; (1): CD001190
Loy C, Schneider L. Galantamine for Alzheimer's disease. Cochrane Database Syst Rev 2004; (4): CD001747
Birks J, Grimley EJ, Iakovidou V, et al. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev 2000; (4): CD001191
Rockwood K. Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004; 75 (5): 677-85
NICE. Press release 2006/048 Oct 18 [online]. Available from URL: http://www.nice.org.uk [Accessed 2006 Sep 29]
Maelicke A, Samochocki M, Jostock R, et al. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biol Psychiatry 2001; 49 (3): 279-88
Greig NH, Utsuki T, Yu Q, et al. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase. Curr Med Res Opin 2001; 17 (3): 159-65
Wilkinson DG, Francis PT, Schwam E, et al. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy. Drugs Aging 2004; 21 (7): 453-78
Bartorelli L, Giraldi C, Saccardo M, et al. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease. Curr Med Res Opin 2005; 21 (11): 1809-18
Bullock R, Touchon J, Bergman H, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin 2005; 21 (8): 1317-27
Pirttila T, Wilcock G, Truyen L, et al. Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial. Eur J Neurol 2004; 11 (11): 734-41
Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology. 1998; 50 (1): 136-45
Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004; 363 (9427): 2105-15
National Library of Medicine. ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2006 Sep 29]
Szekely CA, Thorne JE, Zandi PP, et al. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 2004; 23 (4): 159-69
Hull M, Lieb K, Fiebich BL. Anti-inflammatory drugs: a hope for Alzheimer's disease? Expert Opin Investig Drugs 2000; 9 (4): 671-83
Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000; 21 (3): 383-421
Tabet N, Feldman H. Indomethacin for the treatment of Alzheimer's disease patients. Cochrane Database Syst Rev 2002; (2): CD003673
Dvir E, Friedman JE, Lee JY, et al. A novel phospholipid derivative of indomethacin, DP-155 [mixture of 1-steroyl and 1-palmitoyl-2-{4-[1-(p- chlorobenzoyl)-5-methoxy-2-methyl-3-indolylacetamido]butanoyl} -sn-glycero-3-phosophatidylcho line], shows superior safety and similar efficacy in reducing brain amyloid beta in an Alzheimer's disease model. J Pharmacol Exp Ther 2006; 318 (3): 1248-56
Imbimbo BP. The potential role of non-steroidal anti-inflammatory drugs in treating Alzheimer's disease. Expert Opin Investig Drugs 2004; 13 (11): 1469-81
Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003; 289 (21): 2819-26
Zanetti O, Bonomini C, Pasqualetti P, et al. Effects of ibuprofen on Alzheimer's disease cognitive progression: a randomized controlled trial [abstract]. Alzheimers Dementia 2006; 2 (3 Suppl. 1): S366
Klegeris A, McGeer PL. Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents in the treatment of neurodegenerative disease. Curr Alzheimer Res 2005; 2 (3): 355-65
Weggen S, Eriksen JL, Das P, et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001; 414 (6860): 212-6
Takahashi Y, Hayashi I, Tominari Y, et al. Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces Abeta 42 generation. J Biol Chem 2003; 278 (20): 18664-70
Zhou Y, Su Y, Li B, et al. Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho. Science 2003; 302 (5648): 1215-7
Shie FS, Montine KS, Breyer RM, et al. Microglial EP2 as a new target to increase amyloid beta phagocytosis and decrease amyloid beta-induced damage to neurons. Brain Pathol 2005; 15 (2): 134-8
Waschbisch A, Fiebich BL, Akundi RS, et al. Interleukin-1 beta-induced expression of the prostaglandin E-receptor subtype EP3 in U373 astrocytoma cells depends on protein kinase C and nuclear factor-kappaB. J Neurochem 2006; 96 (3): 680-93
Slawik H, Volk B, Fiebich B, et al. Microglial expression of prostaglandin EP3 receptor in excitotoxic lesions in the rat striatum. Neurochem Int 2004; 45 (5): 653-60
Kawano T, Anrather J, Zhou P, et al. Prostaglandin E(2) EP1 receptors: downstream effectors of COX-2 neurotoxicity. Nat Med 2006; 12 (2): 225-9
Gasparini L, Ongini E, Wilcock D, et al. Activity of flurbiprofen and chemically related anti-inflammatory drugs in models of Alzheimer's disease. Brain Res Brain Res Rev 2005; 48 (2): 400-8
Eriksen JL, Sagi SA, Smith TE, et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest 2003; 112 (3): 440-9
Gordon ML, Mirza N, Bauer L, et al. Intravenous pulse cyclophosphamide in Alzheimer's disease: results of a pilot dose finding study [abstract]. Alzheimers Dementia 2006; 2 (3 Suppl. 1): S360
Henderson VW. Estrogen-containing hormone therapy and Alzheimer's disease risk: understanding discrepant inferences from observational and experimental research. Neuroscience 2006; 138 (3): 1031-9
Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003; 289 (20): 2651-62
Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA 2000; 283 (8): 1007-15
Yaffe K, Vittinghoff E, Ensrud KE, et al. Effects of ultra low-dose transdermal estradiol on cognitive function: results of a randomized clinical trial [abstract]. Alzheimer's Dementia 2006; 2 (3 Suppl. 1): S360
National Institute on Aging. Alzheimer's disease: therapeutic potential of estrogen [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2006 Aug 21]
Maki PM. Hormone therapy and risk for dementia: where do we go from here? Gynecol Endocrinol 2004; 19 (6): 354-9
Brinton RD. Impact of estrogen therapy on Alzheimer's disease: a fork in the road? CNS Drugs 2004; 18 (7): 405-22
Behl C. Oxidative stress in Alzheimer's disease: implications for prevention and therapy. Subcell Biochem 2005; 38: 65-78
Weill-Engerer S, David JP, Sazdovitch V, et al. Neurosteroid quantification in human brain regions: comparison between Alzheimer's and nondemented patients. J Clin Endocrinol Metab 2002; 87 (11): 5138-43
Hunter-Fleming Ltd. European study of HF0220 in mild to moderate Alzheimer's disease patients [online]. Available from URL: http://www. clinicaltrials.gov [Accessed 2006 Aug 17]
Gregory CW, Atwood CS, Smith MA, et al. Antigonadotropins: a novel strategy to halt Alzheimer's disease progression. Curr Pharm Des 2006; 12 (6): 685-90
LaPlante BJ, Powers CF, Gault JL, et al. Stabilization of cognitive decline in Alzheimer's disease following treatment with leuprolide acetate. Alzheimer's Dementia 2006; 2 (3 Suppl. 1): S620-1
Voyager Pharmaceuticals. ALADDIN Study phase III: Antigonadotropin- Leuprolide in Alzheimer's Disease Drug INvestigation (VP-AD-301) [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2006 Aug 20]
National Institute on Aging. SMART: Somatotrophins, Memory, and Aging Research Trial [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2006 Aug 17]
Ryan JM, Ma GJ, Peng Y, et al. A randomized double-blind, placebo-controlled trial to evaluate the safety and efficacy of MK-0677 in slowing the progression of Alzheimer's disease [online]. Available from URL: http://www.alz.org/icad/abstracts.asp [Accessed 2006 Aug 21]
Zandi PP, Sparks DL, Khachaturian AS, et al. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry 2005; 62 (2): 217-24
Simons M, Schwarzler F, Lutjohann D, et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 2002; 52 (3): 346-50
Sparks DL, Sabbagh MN, Connor DJ, et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 2005; 62 (5): 753-7
National Institute on Aging. Cholesterol Lowering Agent to Slow Progression (CLASP) of Alzheimer's disease study [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2006 Aug 17]
Institute for the Study of Aging. Lipitor as a treatment for Alzheimer's disease [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2006 Aug 17]
Wolozin B. Cholesterol, statins and dementia. Curr Opin Lipidol 2004; 15 (6): 667-72
Yrjanheikki J, Koistinaho J, Kettunen M, et al. Long-term protective effect of atorvastatin in permanent focal cerebral ischemia. Brain Res 2005; 1052 (2): 174-9
Sparks DL, Sabbagh M, Connor D, et al. Statin therapy in Alzheimer's disease. Acta Neurol Scand Suppl 2006; 185: 78-86
Butterfield DA, Howard BJ, LaFontaine MA. Brain oxidative stress in animal models of accelerated aging and the age-related neurodegenerative disorders, Alzheimer's disease and Huntington's disease. Curr Med Chem 2001; 8 (7): 815-28
Luchsinger JA, Tang MX, Shea S, et al. Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol 2003; 60 (2): 203-8
Boothby LA, Doering PL. Vitamin C and vitamin E for Alzheimer's disease. Ann Pharmacother 2005; 39 (12): 2073-80
Salerno-Kennedy R, Cashman KD. Relationship between dementia and nutrition-related factors and disorders: an overview. Int J Vitam Nutr Res 2005; 75 (2): 83-95
Tabet N, Birks J, Grimley EJ. Vitamin E for Alzheimer's disease. Cochrane Database Syst Rev 2000; (4): CD002854
Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005; 352 (23): 2379-88
Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 1997 Apr 24; 336 (17): 1216-22
National Institute on Aging. Prevention of Alzheimer's Disease by VItamin E and SElenium (PREADVISE) [online]. Available from URL: http://www. clinicaltrials.gov [Accessed 2006 Aug 17]
Tucker JM, Townsend DM. Alpha-tocopherol: roles in prevention and therapy of human disease. Biomed Pharmacother 2005; 59 (7): 380-7
National Institute on Aging. Anti-oxidant treatment of Alzheimer's disease [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2006 Aug 17]
Birks J, Flicker L. Selegiline for Alzheimer's disease. Cochrane Database Syst Rev 2003; (1): CD000442
Youdim MB, Fridkin M, Zheng H. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases. Mech Ageing Dev 2005; 126 (2): 317-26
Youdim MB, Weinstock M. Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL) -ethyl methyl carbamate]. Cell Mol Neurobiol 2001; 21 (6): 555-73
Metzger E, Wissmann M, Yin N, et al. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 2005; 437 (7057): 436-9
Stocchi F, Olanow CW. Neuroprotection in Parkinson's disease: clinical trials. Ann Neurol 2003; 53 Suppl. 3: S87-97
Esai Medical Research Inc. Rasagiline 1mg and 2mg added to Arizept 10mg daily in patients with mild to moderate Alzheimer's disease (AD) [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2006 Aug 17]
Hynd MR, Scott HL, Dodd PR. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem Int 2004; 45 (5): 583-95
Lipton SA. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism. Curr Alzheimer Res 2005; 2 (2): 155-65
McShane R, Areosa SA, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006; 19; (2): CD003154
Memory Pharmaceuticals. Safety and efficacy of MEM 1003 versus placebo in patients with mild to moderate Alzheimer's disease [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2006 Aug 17]
Lopez-Arrieta JM, Birks J. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev 2002; (3): CD000147
Tariot PN, Loy R, Ryan JM, et al. Mood stabilizers in Alzheimer's disease: symptomatic and neuroprotective rationales. Adv Drug Deliv Rev 2002; 54 (12): 1567-77
ONO Pharma. Effects of ONO-2506PO in patients with Alzheimer's disease [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2006 Aug 17]
Fumagalli F, Racagni G, Riva MA. The expanding role of BDNF: a therapeutic target for Alzheimer's disease? Pharmacogenomics J 2006; 6 (1): 8-15
Tuszynski MH, Blesch A. Nerve growth factor: from animal models of cholinergic neuronal degeneration to gene therapy in Alzheimer's disease. Prog Brain Res 2004; 146: 441-9
Ramirez JJ, Parakh T, George MN, et al. The effects of neotrofin on septodentate sprouting after unilateral entorhinal cortex lesions in rats. Restor Neurol Neurosci 2002; 20 (1-2): 51-9
Apfel SC. Neurotrophic factor therapy: prospects and problems. Clin Chem Lab Med 2001; 39 (4): 351-5
Grundman M, Capparelli E, Kim HT, et al. A multicenter, randomized, placebo controlled, multiple-dose, safety and pharmacokinetic study of AIT-082 (neotrofin) in mild Alzheimer's disease patients. Life Sci 2003; 73 (5): 539-53
Sanofi-Aventis. Long-term safety extension with SR57667B in patients with Alzheimer's disease [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2006 Aug 17]
Sanofi-Aventis. Study of xaliproden (SR57746A) in patients with mild to moderate dementia of the Alzheimer's type [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2006 Aug 17]
Tuszynski MH, Thal L, Pay M, et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005; 11 (5): 551-5
Salehi A, Delcroix JD, Swaab DF. Alzheimer's disease and NGF signaling. J Neural Transm 2004; 111 (3): 323-45
Walter J, Kaether C, Steiner H, et al. The cell biology of Alzheimer's disease: uncovering the secrets of secretases. Curr Opin Neurobiol 2001; 11 (5): 585-90
Ohyagi Y, Asahara H, Chui DH, et al. Intracellular Abeta42 activates p53 promoter: a pathway to neurodegeneration in Alzheimer's disease. FASEB J 2005; 19 (2): 255-7
Hardy J. Toward Alzheimer therapies based on genetic knowledge. Annu Rev Med 2004; 55: 15-25
Kohler C, Ebert U, Baumann K, et al. Alzheimer's disease-like neuropathology of gene-targeted APP-SLxPS1mut mice expressing the amyloid precursor protein at endogenous levels. Neurobiol Dis 2005; 20 (2): 528-40
Gold G, Kovari E, Corte G, et al. Clinical validity of A beta-protein deposition staging in brain aging and Alzheimer disease. J Neuropathol Exp Neurol 2001; 60 (10): 946-52
Vassar R, Bennett BD, Babu-Khan S, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999; 286 (5440): 735-41
Roberds SL, Anderson J, Basi G, et al. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum Mol Genet 2001; 10 (12): 1317-24
Dewachter I, Van Leuven F. Secretases as targets for the treatment of Alzheimer's disease: the prospects. Lancet Neurol 2002; 1 (7): 409-16
Garino C, Tomita T, Pietrancosta N, et al. Naphthyl and coumarinyl biarylpiperazine derivatives as highly potent human beta-secretase inhibitors: design, synthesis, and enzymatic BACE-1 and cell assays. J Med Chem 2006; 49 (14): 4275-85
Citron M. Strategies for disease modification in Alzheimer's disease. Nat Rev Neurosci 2004; 5 (9): 677-85
Koo EH. The beta-amyloid precursor protein (APP) and Alzheimer's disease: does the tail wag the dog? Traffic 2002; 3 (11): 763-70
Cao X, Sudhof TC. Dissection of amyloid-beta precursor protein-dependent transcriptional transactivation. J Biol Chem 2004; 279 (23): 24601-11
De Strooper B, Annaert W, Cupers P, et al. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 1999; 398 (6727): 518-22
Washburn T, Schweighoffer E, Gridley T, et al. Notch activity influences the alphabeta versus gammadelta T cell lineage decision. Cell 1997; 88 (6): 833-43
Pollack SJ, Lewis H. Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous protease. Curr Opin Investig Drugs 2005; 6 (1): 35-47
Dovey HF, John V, Anderson JP, et al. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem 2001; 76 (1): 173-81
Anderson JJ, Holtz G, Baskin PP, et al. Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897. Biochem Pharmacol 2005; 69 (4): 689-98
Micchelli CA, Esler WP, Kimberly WT, et al. Gamma-secretase/presenilin inhibitors for Alzheimer's disease phenocopy notch mutations in drosophila. FASEB J 2003; 17 (1): 79-81
Hartmann D, Tournoy J, Saftig P, et al. Implication of APP secretases in notch signaling. J Mol Neurosci 2001; 17 (2): 171-81
Lammich S, Okochi M, Takeda M, et al. Presenilin-dependent intramembrane proteolysis of CD44 leads to the liberation of its intracellular domain and the secretion of an Abeta-like peptide. J Biol Chem 2002; 277 (47): 44754-9
Kim DY, Ingano LA, Kovacs DM. Nectin-1alpha, an immunoglobulin-like receptor involved in the formation of synapses, is a substrate for presenilin/gamma-secretase-like cleavage. J Biol Chem 2002; 277 (51): 49976-81
Marambaud P, Wen PH, Dutt A, et al. A CBP binding transcriptional repressor produced by the PS1/epsilon-cleavage of N-cadherin is inhibited by PS1 FAD mutations. Cell 2003; 114 (5): 635-45
May P, Reddy YK, Herz J. Proteolytic processing of low density lipoprotein receptor-related protein mediates regulated release of its intracellular domain. J Biol Chem 2002; 277 (21): 18736-43
May P, Bock HH, Nimpf J, et al. Differential glycosylation regulates processing of lipoprotein receptors by gamma-secretase. J Biol Chem 2003; 278 (39): 37386-92
Zou Z, Chung B, Nguyen T, et al. Linking receptor-mediated endocytosis and cell signaling: evidence for regulated intramembrane proteolysis of megalin in proximal tubule. J Biol Chem 2004; 279 (33): 34302-10
Taniguchi Y, Kim SH, Sisodia SS. Presenilin-dependent 'gamma-secretase' processing of deleted in colorectal cancer (DCC). J Biol Chem 2003; 278 (33): 30425-8
Saura CA, Choi SY, Beglopoulos V, et al. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron 2004; 42 (1): 23-36
Tournoy J, Bossuyt X, Snellinx A, et al. Partial loss of presenilins causes seborrheic keratosis and autoimmune disease in mice. Hum Mol Genet 2004; 13 (13): 1321-31
Rosen LB, Stone JA, Plump A, et al. The gamma secretase inhibitor MK-0752 acutely and significantly reduces CSF Abeta40 concentrations in humans. Alzheimers Dementia 2006; 2 (3 Suppl. 1): S79
Siemers ER, Quinn JF, Kaye J, et al. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 2006; 66 (4): 602-4
Effects of LY450139 dihydrate on subjects with mild to moderate Alzheimer's disease [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2006 Aug 17]
Mintzer JE, Wilcock GK, Black SE, et al. MPC-7869 (R-furbiprofen), a selective Abeta42-lowering agent, delays time to clinically significant psychiatric events in Alzheimer's disease: analysis from a 12-month phase 2 trial. Alzheimers Dementia 2006; 2 (3 Suppl. 1): S368
Wilcock GK, Black SE, Haworth J, et al. Efficacy and safety of MPC-7869 (R-flurbipofen), a selective Abeta42-lowering agent, in Alzheimer's disease: results of a 12 month phase 2 trial and a 1-year follow-on study. Alzheimers Dementia 2006; 2 (3 Suppl. 1): S81-2
Myriad Pharmaceuticals. Global efficcy study of MPC-7869 to treat patients with Alzheimer's [online]. Available from URL: http://www. clinicaltrials.gov [Accessed 2006 Aug 17]
Kojro E, Fahrenholz F. The non-amyloidogenic pathway: structure and function of alpha-secretases. Subcell Biochem 2005; 38: 105-27
Lichtenthaler SF, Haass C. Amyloid at the cutting edge: activation of alpha-secretase prevents amyloidogenesis in an Alzheimer disease mouse model. J Clin Invest 2004; 113 (10): 1384-7
Postina R, Schroeder A, Dewachter I, et al. A disintegrin- metalloproteinase prevents amyloid plaque formation and hip pocampal defects in an Alzheimer disease mouse model. J Clin Invest 2004; 113 (10): 1456-64
Iwata N, Tsubuki S, Takaki Y, et al. Metabolic regulation of brain Abeta by neprilysin. Science 2001; 292 (5521): 1550-2
Yasojima K, McGeer EG, McGeer PL. Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain. Brain Res 2001; 919 (1): 115-21
Higuchi M, Iwata N, Saido TC. Understanding molecular mechanisms of proteolysis in Alzheimer's disease: progress toward therapeutic interventions. Biochim Biophys Acta 2005; 1751 (1): 60-7
Saito T, Iwata N, Tsubuki S, et al. Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation. Nat Med 2005; 11 (4): 434-9
Eckman EA, Watson M, Marlow L, et al. Alzheimer's disease beta-amyloid peptide is increased in mice deficient in endothelin-converting enzyme. J Biol Chem 2003; 278 (4): 2081-4
Farris W, Mansourian S, Chang Y, et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A 2003; 100 (7): 4162-7
Yan P, Hu X, Song H, et al. Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. J Biol Chem 2006; 281 (34): 24566-74
Seubert P, Vigo-Pelfrey C, Esch F, et al. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 1992; 359 (6393): 325-7
Shoji M, Golde TE, Ghiso J, et al. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science 1992; 258 (5079): 126-9
Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 2003; 26: 267-98
Lorenzo A, Yankner BA. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc Natl Acad Sci U S A 1994; 91 (25): 12243-7
Pappolla M, Bozner P, Soto C, et al. Inhibition of Alzheimer beta-fibrillogenesis by melatonin. J Biol Chem 1998; 273 (13): 7185-8
Gestwicki JE, Crabtree GR, Graef IA. Harnessing chaperones to generate small-molecule inhibitors of amyloid beta aggregation. Science 2004; 306 (5697): 865-9
Gordon DJ, Sciarretta KL, Meredith SC. Inhibition of beta-amyloid(40) fibrillogenesis and disassembly of beta-amyloid(40) fibrils by short beta-amyloid congeners containing N-methyl amino acids at alternate residues. Biochemistry 2001; 40 (28): 8237-45
Sadowski M, Pankiewicz J, Scholtzova H, et al. A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice. Am J Pathol 2004; 165 (3): 937-48
Adessi C, Frossard MJ, Boissard C, et al. Pharmacological profiles of peptide drug candidates for the treatment of Alzheimer's disease. J Biol Chem 2003; 278 (16): 13905-11
Aisen PS. The development of anti-amyloid therapy for Alzheimer's disease: from secretase modulators to polymerisation inhibitors. CNS Drugs 2005; 19 (12): 989-96
